Taciana de Albuquerque Pedrosa Fernandes

Taciana de Albuquerque Pedrosa Fernandes

Auto-generated profile, based on publicly available information

Taciana de Albuquerque Pedrosa Fernandes

Pediatric Rheumatology Divison, Botucatu Medical School, São Paulo State University (UNESP), Botucatu, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2024 in Current Allergy and Asthma Reports
Verified
Journal Article
Open access
PDF file
AAAmita Aggarwal
Amita Aggarwal
TFTaciana A. P. Fernandes
Taciana A. P. Fernandes
AMAngela Migowa
Angela Migowa
ESEve M. D. Smith
Eve M. D. Smith
MHMaria Hanif
Maria Hanif
LLLaura B. Lewandowski
Laura B. Lewandowski
Purpose of Review Childhood-onset systemic lupus erythematosus (cSLE) is a severe and potentially life-threatening chronic autoimmune disease. cSLE is more aggressive and has poorer outcomes than adult-onset disease. The global burden of cSLE is poorly understood, with most publications on cSLE originating from high-resourced settings. The reports from less resourced settings indicate high morbidity and mortality in these populations. Recent Findings In this article, we review the disparities in global access to rheumatology care and research for patients with cSLE. We highlight recent cSLE advances from all regions of the globe. We describe current obstacles to cSLE clinical care and research in all settings. Finally, we propose a path forward for high quality, equitable and accessible care to individuals with cSLE everywhere. Summary Individuals with cSLE are at risk for morbidity and death, yet patients worldwide face challenges to adequate access to care and research. Sustained, collaborative efforts are needed to create pathways to improve care and outcomes for these patients.

6 February 2024 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
MBMatheus Zanata Brufatto
Matheus Zanata Brufatto
SLSean Hideo Shirata Lanças
Sean Hideo Shirata Lanças
TFTaciana de Albuquerque Pedrosa Fernandes
Taciana de Albuquerque Pedrosa Fernandes
ASAdriana Maluf Elias Sallum
Adriana Maluf Elias Sallum
LCLucia MA Campos
Lucia MA Campos
CSClaudia Saad-Magalhaes
Claudia Saad-Magalhaes
Background: Increased malignancy frequency is well documented in adult-systemic lupus erythematosus (SLE), but with limited reports in childhood-onset SLE (cSLE) series. We explored the frequency of malignancy associated with cSLE, describing clinical and demographic characteristics, disease activity and cumulative damage, by the time of malignancy diagnosis. Method: A retrospective case-notes review, in a nationwide cohort from 27 Pediatric Rheumatology centres, with descriptive biopsy-proven malignancy, disease activity/damage accrual, and immunosuppressive treatment were compiled in each participating centre, using a standard protocol. Results: Of the 1757 cSLE cases in the updated cohort, 12 (0.7%) developed malignancy with median time 10 years after cSLE diagnosis. There were 91% females, median age at cSLE diagnosis 12 years, median age at malignancy diagnosis 23 years. Of all diagnosed malignancies, 11 were single-site, and a single case with concomitant multiple sites; four had haematological (0.22%) and 8 solid malignancy (0.45%). Median (min–max) SLEDAI-2 K scores were 9 (0–38), median (min–max) SLICC/ACR-DI (SDI) score were 1 (1–5) Histopathology defined 1 Hodgkin's lymphoma, 2 non-Hodgkin's lymphoma, 1 acute lymphoblastic leukaemia; 4 gastrointestinal carcinoma, 1 squamous cell carcinoma of the tongue and 1 anal carcinoma; 1 had sigmoid adenocarcinoma and 1 stomach carcinoid; 3 had genital malignancy, being 1 vulvae, 1 cervix and 1 vulvae and cervix carcinomas; 1 had central nervous system oligodendroglioma; and 1 testicle germ cell teratoma. Conclusion: Estimated malignancy frequency of 0.7% was reported during cSLE follow up in a multicentric series. Median disease activity and cumulative damage scores, by the time of malignancy diagnoses, were high; considering that reported in adult series.

8 August 2025 in Lupus
Verified
Journal Article
Closed access
SLSean Hideo Shirata Lanças
Sean Hideo Shirata Lanças
MFMatheus Zanata Brufatto Furlan
Matheus Zanata Brufatto Furlan
ABAndrea de Almeida Peduti Batista
Andrea de Almeida Peduti Batista
SDSula Glaucia Lage Drumond
Sula Glaucia Lage Drumond
TFTaciana de Albuquerque Pedrosa Fernandes
Taciana de Albuquerque Pedrosa Fernandes
CCCintia Zumstein Camargo
Cintia Zumstein Camargo
Background: Systemic Lupus Erythematosus (SLE) is a heterogeneous multisystem autoimmune disease, with variable severity, autoantibody profile, response to treatment, relapsing course and damage accrual. The age at disease onset may influence disease trajectory and prognosis, with remarkable differences of major organ involvement, disease activity, and prognosis. SLE clinical profile, activity indices, remission, and damage comparison were carried out in childhood-onset (cSLE), adult-onset (aSLE) and late-onset (lSLE) patients from a single-centre series. Methods: A cross-sectional analysis reviewing the clinical profile of SLE cases seen between 2012 and 2022 and classified in 3 age-groups according to disease onset: cSLE (=50 years), was performed. Disease activity status was assessed by PGA (0-3), SLEDAI-2K, SLE-DAS, LLDAS and DORIS criteria, and damage using SDI at the same visit were compared in those 3 age-groups. Results: Four hundred and fifteen patients were included in the analysis: 289 (68%) aSLE, 79 (19%) cSLE, and 47 (11.3%) lSLE. Most common clinical manifestations were articular (75.2%), hematological (70.1%), cutaneous (67.9%), photosensitivity (59.3%), and renal (41.7%). The clinical profile was similar among the subgroups of SLE patients, except for lSLE with lower frequency of nephritis and serositis, lower frequency of autoantibodies and hypocomplementenemia, lower SLEDAI-2K and SLE-DAS scores, and a higher frequency of LLDAS and DORIS remission; and a higher damage scores (SDI). Patients with cSLE had a significantly higher frequency of renal and neurological involvement, and a longer disease duration, but the disease activity, damage scores and remission rates were comparable to adult-onset group. Conclusion: The remarkable differences among the 3-age-groups were higher frequency of renal and neuropsychiatric domains in youngsters and disease activity scores compared to other age-groups. The lSLE group had less nephritis and serositis, lower disease activity and higher damage scores.

31 March 2021 in Revista Paulista de Reumatologia
Verified
Journal Article
Closed access
TFTaciana de Albuquerque Pedrosa Fernandes
Taciana de Albuquerque Pedrosa Fernandes
FGFrancisco Hugo Rodrigues Gomes
Francisco Hugo Rodrigues Gomes
FKFabíola Donato de Almeida Kuchiki
Fabíola Donato de Almeida Kuchiki
Resumo: Na última década houve um aumento crescente no uso de medicações biológicas no tratamento de doenças reumáticas autoimunes pediátricas. A maioria desses tratamentos é usada para a artrite idiopática juvenil, mas alguns já estão sendo estudados e aprovados para o tratamento de casos refratários de lúpus eritematoso sistêmico juvenil, dermatomiosite juvenil, síndromes autoinflamatórias e algumas vasculites. Esses fármacos têm mostrado bons perfis de eficácia e segurança na faixa etária pediátrica e trouxeram uma melhora na qualidade de vida dos pacientes com doenças reumáticas crônicas refratárias à terapêutica convencional. Recomendações de preparo do paciente (rastreio de infecções e vacinações), forma de utilização (vias de administração, doses e intervalos), eventos adversos (principais eventos, prevenção, tratamento), monitorização do paciente e apresentações disponíveis desses medicamentos estão sumarizados no artigo. Unitermos: Doença autoimune. Imunobiológicos. Anticorpos monoclonais. Proteínas de fusão. Reumatologia pediátrica.

21 November 2024 in Research Square
Verified
Preprint
Open access
PDF file
DLDouglas Squizatto Leite
Douglas Squizatto Leite
LCLucas Silva Cortes
Lucas Silva Cortes
MDMaria Aparecida Maria Aparecida Custódio Domingues
Maria Aparecida Maria Aparecida Custódio Domingues
CMClaudia Saad Magalhaes
Claudia Saad Magalhaes
TFTaciana de Albuquerque Pedrosa Fernandes
Taciana de Albuquerque Pedrosa Fernandes
Objective: Explore clinical, demographic and histopathologic features of pediatric hyperinflammatory manifestations associated to SARS-CoV-2, observed during the COVID-19 pandemic, and the relationship of Multisystemic Inflammatory Syndrome of Childhood (MIS-C) with other inflammatory and autoimmune manifestations, such as macrophage activation syndrome, vasculitis and vasculopathy. Methods: A protocol with detailed socio-demographic and clinical features, SARS-CoV-2 exposure and morbidity was conducted in a public tertiary hospital as part of a multicentric international protocol. Cases were selected and enrolled in a single centre from 2020 to 2022, recording all the organ and systems manifestations, standard treatment and outcome. Results: Of the 23 suspicious cases, 21 met the inclusion criteria of MIS-C. Gastrointestinal manifestations were frequent, and three out of 21 had acute abdomen, one with documented histiocytic necrotizing lymphadenopathy (HNL), 3 had macrophage activation syndrome (MAS), and one case, with previous enthesitis related arthritis evolved into type V Takayasu arteritis and malignant hypertension. All patients were treated with either intravenous immunoglobulin (IVIG), high dose glucocorticoids or both, five were under intensive care treatment with respiratory and cardio-circulatory support. All had full recovery during acute phase. Description the HNL histopathology showed proliferation of small lymphocytes and macrophage infiltrates with microthrombi and lymph nodes germinal centers necrosis. Conclusion: Post-infectious hyperinflammatory states associated with COVID manifestations may cause not only to transient inflammatory features, but also autoimmunity, vasculitis and vasculopathy manifestations that require prompt treatment.

2 December 2025 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
DLDouglas Squizatto Leite
Douglas Squizatto Leite
LCLucas Silva Cortes
Lucas Silva Cortes
MDMaria Aparecida Custódio Domingues
Maria Aparecida Custódio Domingues
CMClaudia Saad Magalhaes
Claudia Saad Magalhaes
TFTaciana de Albuquerque Pedrosa Fernandes
Taciana de Albuquerque Pedrosa Fernandes
Objective: Explore clinical features, atypical manifestations and rare autoimmune complications of pediatric hyperinflammatory manifestations associated to SARS-CoV-2, observed during the COVID-19 pandemic, and the relationship of Multisystemic Inflammatory Syndrome of Childhood (MIS-C) with other manifestations, such as macrophage activation syndrome, vasculitis and vasculopathy. Methods: A protocol with detailed socio-demographic and clinical features, SARS-CoV-2 exposure and morbidity was conducted in a public tertiary hospital as part of a multicentric international protocol. Cases were selected and enrolled in a single centre from 2020 to 2022, recording all the organ and systems manifestations, standard treatment and outcome. Results: Of the 23 suspicious cases, 21 met the inclusion criteria of MIS-C. Gastrointestinal manifestations were frequent, and three out of 21 had acute abdomen, one with documented histiocytic necrotizing mesenteric lymphadenopathy (Kikuchi-Fujimoto), 3 had macrophage activation syndrome (MAS), and one case, with previous enthesitis related arthritis evolved into type V Takayasu arteritis and malignant hypertension. All patients were treated with either intravenous immunoglobulin (IVIG), high dose glucocorticoids or both, five were under intensive care treatment with respiratory and cardio-circulatory support. All had full recovery during acute phase. Description the lymphonode histopathology showed proliferation of small lymphocytes and macrophage infiltrates with microthrombi and lymph nodes germinal centers necrosis. Conclusion: Post-infectious hyperinflammatory states associated with COVID-19 manifestations may cause not only to transient inflammatory features, but also autoimmunity, vasculitis and vasculopathy manifestations that require prompt treatment.